Merck Shareholders Win Cert. In Vioxx Stock Fraud MDL

Law360, New York (January 31, 2013, 6:09 PM EST) -- A New Jersey federal judge on Wednesday certified a class of Merck & Co. Inc. investors who've claimed for years that company executives artificially boosted the drugmaker's stock price by concealing evidence that its arthritis painkiller Vioxx had been linked to heart attack risks.

In a coup for the plaintiffs, the judge granted class status to all shareholders who lost money on Merck common stock or options trades between May 1999 and September 2004, the same month the drug was pulled from U.S. shelves amid mounting...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.